Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Not Recruiting

Trial ID: NCT04533750

Purpose

This phase I trial investigates the side effects and best dose of peposertib when given together with radiation therapy in treating patients with head and neck cancer that has spread to other places in the body (advanced) who cannot take cisplatin. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This trial aims to see whether adding peposertib to radiation therapy is safe and works well in treating patients with head and neck cancer.

Official Title

Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Stanford Investigator(s)

Saad A. Khan, MD
Saad A. Khan, MD

Associate Professor of Medicine (Oncology)

Eligibility


Inclusion Criteria:

   - Pathologically (histologically) proven diagnosis of HNSCC of the oral cavity,
   oropharynx, larynx, or hypopharynx prior to registration;

      - Patients with oropharynx cancer need p16 determination by immunohistochemistry
      (where positive is defined as greater than 70% strong nuclear or nuclear and
      cytoplasmic staining of tumor cells), Note: Institutions must screen patients
      using a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. A
      rigorous laboratory accreditation process similar to the United States (U.S.)
      CLIA certification, such as the provincial accreditation status offered by the
      Ontario Laboratory Accreditation (OLA) Program in Canada, the College of American
      Pathologists (CAP), or an equivalent accreditation in other countries, is
      acceptable. The p16 results must be reported on the pathology report being
      submitted;

      - Oral cavity, larynx, hypopharynx, or p16-negative oropharynx cancer must be
      stages T1-2N2-3 or T3N1-3 or T4N0-3 (American Joint Committee on Cancer [AJCC]
      version 8);

      - p16-positive oropharynx cancer patients, stages T4N0-3 or T1-3N2-3 (AJCC version
      8);

      - The patient has measurable disease as defined by the presence of at least one
      measurable lesion per RECIST 1.1;

      - Please note: A histological or pathological specimen from cervical lymph nodes
      with well-defined primary site documented clinically or radiologically is
      acceptable

   - Clinical stage noted above should be based upon following diagnostic workup:

      - History/physical examination within 30 days prior to registration;

      - Examination by radiation oncologist or medical oncologist or otolaryngology (ENT)
      or head & neck surgeon 30 days prior to registration, including fiber optic exam
      with laryngopharyngoscopy;

      - Diagnostic quality computed tomography (CT) or magnetic resonance imaging (MRI)
      of neck, with contrast, within 30 days prior to registration. Fludeoxyglucose
      F-18 (18F-FDG) whole body positron emission tomography (PET)-CT scan within 42
      days of registration is strongly recommended but does not replace the CT or MRI
      study. Note: If CT component of the PET/CT is of diagnostic quality then PET/CT
      can be used for eligibility, however the PET/CT scan must be done within 30 days
      prior to registration

      - Diagnostic quality, cross sectional imaging of the thorax within 42 days prior to
      registration; 18-F-FDG-PET/CT or conventional CT are acceptable

   - Age >= 18 years

   - Patients must have a contraindication to cisplatin as defined in the following bullet
   points. Sites must complete the online tool at comogram.org prior to registration to
   determine if the patient is eligible. The scores must be recorded on a case report
   form (CRF). (Refer to data submission table on the NRG-HN008 protocol page on the NRG
   website);

      - Age >= 70 with moderate to severe comorbidity, defined as having one or more of
      the following conditions within 30 days prior to registration;

         - Modified Charlson Comorbidity Index >= 1

         - Adult Comorbidity Evaluation (ACE)-27 Index >= 1

         - Omega score < 0.80

         - G-8 score =< 14

         - Cancer and Aging Research Group (CARG) Toxicity Score >= 30%

         - Cumulative Illness Rating Scale for Geriatrics (CIRS-G) Score >= 4 OR

      - Age < 70 with severe comorbidity, defined as having two or more of the following
      conditions within 30 days prior to registration;

         - Modified Charlson Comorbidity Index >= 1

         - ACE-27 Index >= 1

         - Omega score < 0.80

         - G-8 score =< 14

         - CARG Toxicity Score >= 30%

         - CIRS-G Score >= 4 OR

      - Age >= 18 with an absolute or relative contraindication to cisplatin, defined as
      one or more of the following criterion within 30 days prior to registration:

         - Pre-existing peripheral neuropathy grade >= 1;

         - Creatinine clearance (CrCl) must be > 30 and < 60 mL/min

            - For this calculation, use the Cockcroft-Gault formula

         - History of hearing loss, defined as either:

            - Existing need of a hearing aid OR

            - >= 25 decibel shift over 2 contiguous frequencies on a pretreatment
            hearing test as clinically indicated

   - Zubrod Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 30
   days prior to registration

   - Whole blood cell (WBC) >= 2000 cells/mm^3 (within 30 days prior to registration)

   - Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (within 30 days prior to
   registration)

   - Platelets >= 100,000 cells/mm^3 (within 30 days prior to registration)

   - Hemoglobin >= 9.0 g/dL (within 30 days prior to registration); Note: The use of
   transfusion is acceptable

   - Creatinine clearance (CrCl) > 30 mL/min (within 30 days prior to registration)

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) (except patients with Gilbert
   syndrome who can have total bilirubin < 3.0 mg/dL) (within 30 days prior to
   registration)

   - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
   (within 30 days prior to registration)

   - For women of child bearing potential (e.g. uterus present and menstruating), a
   negative serum pregnancy test within 14 days prior to registration. Women of
   childbearing potential (WOCBP) is defined as any female who has experienced menarche
   and who has not undergone surgical sterilization (hysterectomy or bilateral
   oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12
   months of amenorrhea in a woman over 45 in the absence of other biological or
   physiological causes. In addition, women under the age of 55 must have a documented
   serum follicle stimulating hormone (FSH) level less than 40 mIU/mL

   - The patient must provide study-specific informed consent prior to study entry

   - Known human immunodeficiency virus (HIV) infected patients on effective
   anti-retroviral therapy with undetectable viral load within 6 months and CD4 T cell
   count >= 200 are eligible for this trial. Testing is not required for entry into
   protocol

   - Patients with a history of hepatitis B or C infection are eligible if they have an
   undetectable viral load

   - Willing to use highly effective contraceptives for males and females of childbearing
   potential during therapy and for 12 weeks after the last dose of M3814 (peposertib);
   this inclusion is necessary because the treatment in this study may be significantly
   teratogenic

   - Patients must be able to swallow whole tablets

Exclusion Criteria:

   - Definitive clinical or radiologic evidence of distant (beyond cervical lymph node and
   neck tissue) metastatic disease

   - Carcinoma of the neck of unknown primary site origin

   - Patients with oral cavity cancer are excluded from participation if the patient is
   medically operable and the resection of the primary tumor is considered technically
   feasible by an oral or head and neck cancer surgical subspecialist

   - Gross total excision of both primary and nodal disease; this includes tonsillectomy,
   local excision of primary site, and nodal excision that removes all clinically and
   radiographically evident disease

      - Note: Patients with RECIST, version (v.) 1.1 evaluable remaining cancer either in
      the neck or primary site remain eligible

   - Prior invasive malignancy (except non-melanomatous skin cancer carcinoma, in situ of
   the breast, oral cavity, or cervix, low or very low-risk prostate cancer) unless
   disease free for a minimum of 3 years

   - Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
   different cancer is allowable if not within =< 3 years

   - Prior radiotherapy to the region of the study cancer that would result in overlap of
   radiation therapy fields

   - Severe, active co-morbidity defined as follows:

      - History of bone marrow transplant and organ transplant, including allogenic stem
      cell transplantation;

      - Unstable angina requiring hospitalization in the last 6 months;

      - New York Heart Association Functional classification III/IV (Note: Patients with
      known history or current symptoms of cardiac disease, or history of treatment
      with cardiotoxic agents, should have a clinical risk assessment of cardiac
      function using the New York Heart Association Functional Classification.);

      - Myocardial infarction within the last 6 months;

      - Persistent grade 3-4 (Common Terminology Criteria for Adverse Events [CTCAE]
      version 5.0) electrolyte abnormalities that cannot be reversed despite as
      indicated by repeat testing;

      - Ongoing active infection that is associated with symptoms and/or requires
      antibiotic therapy at the time of registration (excluding asymptomatic
      bacteriuria, genital herpes, oral herpes, thrush, bacterial vaginosis, vaginal
      candidiasis, topical antifungals)

   - Pregnancy and nursing females, if applicable

   - Concomitant use of proton pump inhibitors (or unable to stop 5 days prior to
   treatment)

   - Receipt of live vaccinations within 28 days prior to registration

   - Patients unable to discontinue medications or substances that are:

      - Strong inhibitors, inducers or sensitive substrates of CYP3A4/5, CYP2C19, or
      CYP2C9 prior to study treatment;

      - Substrates of CYP1A2, CYP2B6, or CYP3A4/5 with a narrow therapeutic prior to
      study treatment;

         - Note: Opioids are allowed, with the exception of methadone

   - Fridericia's correction formula (QTcF) > 450 ms for males and > 470 ms for females

Intervention(s):

radiation: Intensity-Modulated Radiation Therapy

drug: Peposertib

procedure: Computed Tomography

other: Fludeoxyglucose F-18

procedure: Magnetic Resonance Imaging

procedure: Positron Emission Tomography

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Aja Macias
650-497-7499

New Trial Alerts